Kosh Agarwal
0000-0002-4754-828X
404 papers found
Refreshing results…
Regeneration linked miRNA in acute liver failure can predict clinical recompensation after DAA associated HCV cure: a novel biomarker to inform treatment selection in decompensated HCV cirrhosis?
Comparison of Extended-Release, Once Daily Tacrolimus and Standard Twice Daily Tacrolimus in De Novo Liver Transplant Recipients
Impact of comorbidity on waiting list and post-transplant outcomes in patients undergoing liver retransplantation
Treatment of Genotype 3 Chronic Hepatitis C Virus Infection
Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir I Sofosbuvir Plus Ribavirin Pretransplant
Identification Of Novel Viral Single Nucleotide Variants Associated With Baseline HBV DNA Levels And HBeAg Status In Chronic Hepatitis B Patients
HepFree: A large cluster randomised controlled cross sectional trial to assess screening and treating first and second generation migrants from 'At Risk' countries with chronic viral hepatitis
Does age matter? Direct-acting antiviral therapy for hepatitis C in a real-life cohort of elderly patients: pretreatment drug-drug interactions, tolerability and efficacy of current treatment regimens
Weight based ribavirin with sofosbuvir and daclatasvir for 12 weeks for patients with Genotype 3 Hepatitis C and cirrhosis: An analysis of efficacy and long-term clinical outcomes
Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis
A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg positive and negative virally suppressed subjects with hepatitis B
Virally suppressed patients with chronic HBV infection without cirrhosis have better patient-reported outcomes (PROS)
Predictors of HBeAg loss in HBeAg-positive patients with chronic hepatitis B during treatment with tenofovir alafenamide or tenofovir disoproxil fumarate
Do HBsAg concentrations > 4 log(10)IU/ml represent a risk for mother to child transmission of HBV infection in all chronic hepatitis B patients?
Lowest acquisition drug cost directly acting antiviral (DAA) treatment for hepatitis C (HCV): high cure rates in a difficult to treat HIV/HCV population
Web-based education program improves patient education and understanding of chronic Hepatitis B
HBsAg and HBcrAg as predictors of seroconversion in a pan-genotypic population of hepatitis B e antigen positive patients treated with nucleos(t)ide analogues
MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1–6 infection
HBcrAg, HBV-RNA declines in A Phase 2a Study Evaluating the Multi-dose Activity of ARB-1467 in HBeAg-Positive and Negative Virally Suppressed Subjects with Hepatitis B
The impact of treatment of chronic hepatitis B (CHB) on patient-reported outcomes (PROs)
Missing publications? Search for publications with a matching author name.